[{"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-001", "question": "A 58-year-old man with a history of hypertrophic cardiomyopathy presents with recurrent syncope. Genetic testing reveals a mutation in the MYH7 gene. Echocardiography shows asymmetric septal hypertrophy with a left ventricular outflow tract gradient of 80 mmHg at rest. Despite optimal medical therapy with beta-blockers, he continues to experience symptoms. What is the most appropriate next step in management?", "options": ["Alcohol septal ablation", "Surgical myectomy", "Implantation of a dual-chamber pacemaker", "Addition of disopyramide", "Cardiac resynchronization therapy"], "answer": "D", "answer_index": 3, "explanation": "Addition of disopyramide is the most appropriate next step as it is recommended for symptomatic hypertrophic cardiomyopathy with obstruction refractory to beta-blockers, acting as a negative inotrope to reduce the gradient. Alcohol septal ablation and surgical myectomy are invasive options considered only after failure of medical therapy including disopyramide. Pacemaker implantation and cardiac resynchronization therapy are not first-line for outflow tract obstruction in this context.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To determine the most appropriate next step for this patient with hypertrophic cardiomyopathy (HCM), I'll analyze the key clinical information:\n\n- 58-year-old man with HCM (confirmed by MYH7 gene mutation)\n- Recurrent syncope despite optimal beta-blocker therapy\n- Severe outflow obstruction (LVOT gradient 80 mmHg at rest)\n- Asymmetric septal hypertrophy on echocardiography\n\nFor symptomatic HCM with significant outflow obstruction (gradient >50 mmHg) that persists despite optimal medical therapy, invasive septal reduction therapy is indicated. The two main options are:\n\nA. Alcohol septal ablation - Less invasive but with higher risk of heart block and less complete gradient reduction\nB. Surgical myectomy - Considered the gold standard for severe, drug-refractory obstructive HCM\n\nC. Dual-chamber pacing is now considered a less effective option with limited evidence\nD. Disopyramide would be an additional medication trial before moving to invasive options\nE. CRT is not indicated for HCM management\n\nGiven the patient's severe symptoms (recurrent syncope) despite optimal medical therapy and the significant outflow gradient, surgical myectomy would provide the most definitive treatment.\n\nThe answer is (B)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-002", "question": "A 4-year-old boy with a history of recurrent urinary tract infections is found to have vesicoureteral reflux on voiding cystourethrogram. Renal ultrasound shows mild hydronephrosis. Despite prophylactic antibiotics, he develops breakthrough infections. Genetic evaluation reveals a mutation in the PAX2 gene. What is the most likely associated syndrome?", "options": ["Denys-Drash syndrome", "Renal coloboma syndrome", "Branchio-oto-renal syndrome", "Alport syndrome", "Frasier syndrome"], "answer": "B", "answer_index": 1, "explanation": "Renal coloboma syndrome is associated with PAX2 mutations, characterized by renal hypoplasia, vesicoureteral reflux, and optic nerve colobomas. Denys-Drash and Frasier syndromes involve WT1 mutations, while Alport syndrome relates to collagen IV defects. Branchio-oto-renal syndrome is linked to EYA1 mutations.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To answer this question, I need to identify which syndrome is associated with PAX2 gene mutations.\n\nPAX2 is a transcription factor that plays a critical role in kidney and eye development. Mutations in the PAX2 gene are specifically associated with Renal Coloboma Syndrome (also known as Papillorenal Syndrome). This syndrome is characterized by:\n\n- Renal hypoplasia or other kidney abnormalities\n- Optic nerve colobomas (defects in the structure of the eye)\n- Vesicoureteral reflux (as seen in this patient)\n- Urinary tract abnormalities\n\nThe clinical presentation of this 4-year-old boy with vesicoureteral reflux, hydronephrosis, and recurrent UTIs is consistent with Renal Coloboma Syndrome.\n\nThe other syndromes listed have different genetic causes:\n- Denys-Drash syndrome: WT1 gene mutations\n- Branchio-oto-renal syndrome: EYA1, SIX1, or SIX5 gene mutations\n- Alport syndrome: COL4A3, COL4A4, or COL4A5 gene mutations\n- Frasier syndrome: WT1 gene mutations\n\nThe answer is (B)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-003", "question": "In the emergency department, a 32-year-old woman presents with acute chest pain and dyspnea following a long-haul flight. CT pulmonary angiography confirms a segmental pulmonary embolism. She has a history of oral contraceptive use and a positive family history for thrombophilia. Laboratory testing shows elevated factor VIII levels. What is the most appropriate initial anticoagulant therapy?", "options": ["Low-molecular-weight heparin followed by warfarin", "Direct oral anticoagulant such as rivaroxaban", "Unfractionated heparin with thrombolysis", "Fondaparinux monotherapy", "Aspirin and clopidogrel combination"], "answer": "B", "answer_index": 1, "explanation": "Direct oral anticoagulants like rivaroxaban are preferred for initial treatment of pulmonary embolism in non-pregnant patients without severe renal impairment or active cancer. Low-molecular-weight heparin followed by warfarin is an alternative but less convenient. Thrombolysis is reserved for hemodynamically unstable cases, and antiplatelet therapy is insufficient for venous thromboembolism.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "For this patient with a confirmed segmental pulmonary embolism, I need to determine the most appropriate initial anticoagulant therapy based on the clinical scenario.\n\nThe patient is a 32-year-old woman with:\n- Acute chest pain and dyspnea after a long-haul flight\n- Confirmed segmental pulmonary embolism on CT pulmonary angiography\n- Risk factors: oral contraceptive use, positive family history for thrombophilia\n- Elevated factor VIII levels (a thrombophilia risk factor)\n\nLet me analyze each option:\n\nA. Low-molecular-weight heparin followed by warfarin - This is a standard treatment approach for PE, especially when there are thrombophilia concerns.\n\nB. Direct oral anticoagulant such as rivaroxaban - DOACs are now first-line for most non-massive PEs due to their efficacy, safety profile, and convenience.\n\nC. Unfractionated heparin with thrombolysis - Thrombolysis is typically reserved for massive PE with hemodynamic instability, which this patient doesn't appear to have.\n\nD. Fondaparinux monotherapy - While fondaparinux is effective, it's not typically used as monotherapy for the entire treatment course.\n\nE. Aspirin and clopidogrel combination - Antiplatelet therapy is inadequate for treating PE.\n\nFor a hemodynamically stable patient with a segmental PE, current guidelines favor either LMWH followed by warfarin or a direct oral anticoagulant. Given the patient's thrombophilia risk factors but non-massive PE, a DOAC such as rivaroxaban would be appropriate as initial therapy.\n\nThe answer is (B)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-004", "question": "A 45-year-old woman presents with symmetric polyarthritis, morning stiffness, and a rash on her trunk. Laboratory tests show positive anti-citrullinated protein antibodies and elevated inflammatory markers. Despite methotrexate therapy, her disease progresses. Genetic testing reveals a mutation in the NLRP3 gene. What is the most likely diagnosis?", "options": ["Rheumatoid arthritis", "Cryopyrin-associated periodic syndrome", "Adult-onset Still's disease", "Behçet's disease", "Systemic lupus erythematosus"], "answer": "B", "answer_index": 1, "explanation": "Cryopyrin-associated periodic syndrome involves NLRP3 mutations, presenting with arthritis, rash, and autoinflammatory features that may mimic rheumatoid arthritis but respond poorly to standard DMARDs. Rheumatoid arthritis typically lacks this genetic mutation and responds to methotrexate. Adult-onset Still's disease and others do not feature NLRP3 mutations.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To determine the most likely diagnosis, I'll analyze the clinical presentation and laboratory findings.\n\nThe patient presents with:\n- Symmetric polyarthritis and morning stiffness (suggestive of RA)\n- Rash on trunk\n- Positive anti-citrullinated protein antibodies (highly specific for RA)\n- Elevated inflammatory markers\n- Disease progression despite methotrexate\n- NLRP3 gene mutation\n\nThe symmetric polyarthritis with morning stiffness and positive anti-citrullinated protein antibodies strongly point to rheumatoid arthritis. However, the NLRP3 gene mutation is the key finding here, as it is specifically associated with cryopyrin-associated periodic syndrome (CAPS), which is a group of rare autoinflammatory disorders.\n\nCAPS includes conditions like familial cold autoinflammatory syndrome, Muckle-Wells syndrome, and neonatal-onset multisystem inflammatory disease. These conditions typically present with recurrent fevers, rash, joint pain, and other inflammatory symptoms.\n\nWhile the patient has features suggestive of RA, the genetic finding of NLRP3 mutation makes cryopyrin-associated periodic syndrome the most likely diagnosis.\n\nThe answer is (B)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-005", "question": "A 28-year-old man with type 1 diabetes mellitus presents with recurrent hypoglycemia despite insulin dose adjustments. Continuous glucose monitoring shows nocturnal hypoglycemia. Laboratory evaluation reveals elevated proinsulin levels and a low C-peptide. What is the most likely underlying mechanism?", "options": ["Insulinoma", "Factitious hypoglycemia from exogenous insulin", "Adrenal insufficiency", "Autoimmune hypoglycemia", "Nesidioblastosis"], "answer": "B", "answer_index": 1, "explanation": "Factitious hypoglycemia from exogenous insulin is indicated by low C-peptide and elevated proinsulin due to suppressed endogenous insulin production. Insulinoma would show high C-peptide and proinsulin. Adrenal insufficiency typically causes hyperglycemia, and autoimmune hypoglycemia involves insulin antibodies with variable C-peptide.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To determine the most likely mechanism for this patient's hypoglycemia, I'll analyze the key findings:\n\n1) 28-year-old with type 1 diabetes mellitus\n2) Recurrent hypoglycemia despite insulin adjustments\n3) Nocturnal hypoglycemia\n4) Elevated proinsulin levels\n5) Low C-peptide\n\nIn type 1 diabetes, patients typically have low or undetectable C-peptide because their pancreatic beta cells are destroyed. The low C-peptide here is consistent with the patient's type 1 diabetes.\n\nThe critical finding is elevated proinsulin with low C-peptide. This pattern suggests exogenous insulin administration, as:\n- Exogenous insulin would suppress endogenous insulin production (explaining low C-peptide)\n- Exogenous insulin doesn't contain C-peptide\n- Elevated proinsulin is unusual but could represent cross-reactivity in the assay\n\nInsulinoma (A) would show elevated C-peptide and insulin.\nAdrenal insufficiency (C) wouldn't directly affect proinsulin/C-peptide ratios.\nAutoimmune hypoglycemia (D) typically shows elevated insulin and C-peptide.\nNesidioblastosis (E) would show elevated C-peptide.\n\nThe pattern most consistent with factitious hypoglycemia from excessive exogenous insulin administration.\n\nThe answer is (B)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-006", "question": "A 65-year-old man with ischemic cardiomyopathy and an ejection fraction of 25% develops sustained ventricular tachycardia. He is hemodynamically stable. Electrophysiology study identifies a reentrant circuit in the infarct border zone. Despite amiodarone therapy, episodes recur. What is the most appropriate next intervention?", "options": ["Catheter ablation", "Implantable cardioverter-defibrillator upgrade to biventricular", "Addition of mexiletine", "Stellate ganglionectomy", "Cardiac sympathetic denervation"], "answer": "A", "answer_index": 0, "explanation": "Catheter ablation is the most appropriate for recurrent ventricular tachycardia in ischemic cardiomyopathy refractory to antiarrhythmic drugs, targeting the reentrant circuit. ICD upgrade addresses heart failure but not arrhythmia substrate directly. Mexiletine addition is less effective for scar-related VT, and surgical options like ganglionectomy are reserved for refractory cases.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "To determine the most appropriate next intervention for this patient, I'll analyze the key clinical details:\n\n- 65-year-old man with ischemic cardiomyopathy\n- Low ejection fraction (25%)\n- Sustained ventricular tachycardia (VT) that is hemodynamically stable\n- Electrophysiology study confirmed reentrant circuit in infarct border zone\n- Amiodarone therapy has failed to prevent recurrence\n\nFor patients with recurrent sustained VT due to a specific reentrant circuit that has been identified, catheter ablation is typically the next step when antiarrhythmic medication (like amiodarone) has failed. This is especially true when the circuit has been clearly mapped to the infarct border zone.\n\nWhile an ICD would be indicated for this patient (and he likely already has one given his profile), upgrading to biventricular pacing addresses heart failure but not the specific VT circuit.\n\nAdding mexiletine might be considered but is less effective than targeted ablation when a specific circuit has been identified.\n\nStellate ganglionectomy and cardiac sympathetic denervation are typically reserved for refractory cases or conditions like long QT syndrome or catecholaminergic polymorphic VT, not for post-infarct reentrant VT with a known circuit.\n\nThe answer is (A)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-007", "question": "An 8-year-old girl with short stature and failure to thrive undergoes evaluation. Bone age is delayed, and laboratory tests show low IGF-1 with normal growth hormone stimulation. Genetic testing reveals a mutation in the IGF1R gene. What is the most appropriate management strategy?", "options": ["Recombinant growth hormone therapy", "IGF-1 replacement therapy", "Nutritional supplementation", "Thyroid hormone replacement", "Corticosteroid therapy"], "answer": "B", "answer_index": 1, "explanation": "IGF-1 replacement therapy is indicated for IGF1R mutations causing primary IGF-1 deficiency resistant to growth hormone. Recombinant growth hormone would be ineffective due to receptor defect. Nutritional or hormonal supplements like thyroid or corticosteroids do not address the underlying IGF-1 resistance.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "To address this case, I need to consider the underlying pathophysiology based on the clinical findings.\n\nThe patient presents with:\n- Short stature and failure to thrive\n- Delayed bone age\n- Low IGF-1 levels\n- Normal growth hormone stimulation\n- Mutation in the IGF1R gene\n\nThe IGF1R gene encodes the insulin-like growth factor 1 receptor. Mutations in this gene cause IGF-1 resistance, meaning that even though IGF-1 may be produced, the body cannot respond to it properly because of defective receptors. This explains why the patient has growth issues despite normal growth hormone stimulation.\n\nLet's evaluate each option:\n\nA. Recombinant growth hormone therapy - This would increase GH levels, which could indirectly increase IGF-1 production. Since the primary issue is receptor resistance rather than IGF-1 production, this approach might help by overwhelming the system with more IGF-1, potentially activating the remaining functional receptors.\n\nB. IGF-1 replacement therapy - This would not be effective since the problem is receptor resistance, not IGF-1 deficiency. Adding more IGF-1 when the receptors don't function properly wouldn't address the underlying issue.\n\nC. Nutritional supplementation - While nutrition is important for growth, it won't address the genetic receptor defect.\n\nD. Thyroid hormone replacement - There's no indication of thyroid dysfunction in this case.\n\nE. Corticosteroid therapy - This would likely worsen growth problems, as corticosteroids can inhibit growth.\n\nGiven the IGF1R mutation causing IGF-1 resistance, high-dose recombinant growth hormone therapy is typically the most effective approach, as it can overcome partial resistance by increasing IGF-1 levels substantially.\n\nThe answer is (A)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-008", "question": "In the emergency department, a 50-year-old man presents with severe abdominal pain and vomiting. CT scan shows acute pancreatitis with necrosis. He develops hypotension and acute kidney injury. Serum triglycerides are 1200 mg/dL. What is the most appropriate initial management for the hypertriglyceridemia?", "options": ["Plasmapheresis", "Insulin infusion", "Fibrates", "Niacin", "Statins"], "answer": "B", "answer_index": 1, "explanation": "Insulin infusion effectively lowers triglycerides in hypertriglyceridemic pancreatitis by enhancing lipoprotein lipase activity. Plasmapheresis is reserved for severe cases not responding to insulin. Fibrates, niacin, and statins are long-term therapies not suitable for acute management.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To address hypertriglyceridemia in the setting of acute pancreatitis with necrosis, I need to consider the severity of the condition and the most effective immediate intervention.\n\nThis patient has severe hypertriglyceridemia (1200 mg/dL) that has likely triggered acute pancreatitis. He is critically ill with hypotension and acute kidney injury, indicating a severe inflammatory response.\n\nFor hypertriglyceridemia-induced pancreatitis:\n\nA. Plasmapheresis - Rapidly removes triglycerides from circulation and can quickly lower levels in critical situations. Effective but requires specialized equipment and personnel.\n\nB. Insulin infusion - Activates lipoprotein lipase, promoting triglyceride clearance. Can be started immediately in most hospital settings and is effective for rapid reduction of triglycerides.\n\nC. Fibrates - Oral medications that lower triglycerides but have a delayed onset of action (days to weeks).\n\nD. Niacin - Oral medication with delayed effect and significant side effects.\n\nE. Statins - Primarily lower cholesterol rather than triglycerides and have a delayed effect.\n\nIn this acute, life-threatening situation, the most appropriate initial management is insulin infusion, which can be started immediately and effectively reduces triglyceride levels.\n\nThe answer is (B)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-009", "question": "A 35-year-old woman with seropositive rheumatoid arthritis on infliximab develops fever, weight loss, and lymphadenopathy. Biopsy shows non-caseating granulomas. Serum angiotensin-converting enzyme is elevated. What is the most likely diagnosis?", "options": ["Tuberculosis reactivation", "Infliximab-induced sarcoidosis", "Lymphoma", "Fungal infection", "Amyloidosis"], "answer": "B", "answer_index": 1, "explanation": "Infliximab-induced sarcoidosis is a rare complication of TNF inhibitors, presenting with granulomatous inflammation mimicking sarcoidosis. Tuberculosis would show caseating granulomas and positive cultures. Lymphoma or infections are differentials but less likely without specific evidence.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To answer this question, I need to analyze the clinical presentation and consider the effects of infliximab treatment.\n\nThe patient has:\n- Rheumatoid arthritis on infliximab (TNF-α inhibitor)\n- Fever, weight loss, lymphadenopathy\n- Non-caseating granulomas on biopsy\n- Elevated serum angiotensin-converting enzyme (ACE)\n\nNon-caseating granulomas with elevated ACE levels are classic findings in sarcoidosis. Interestingly, while TNF-α inhibitors like infliximab are sometimes used to treat sarcoidosis, they have paradoxically been reported to induce sarcoidosis-like reactions in some patients.\n\nTuberculosis reactivation is a known risk with TNF-α inhibitors, but TB typically shows caseating granulomas, not non-caseating ones.\n\nLymphoma can occur in RA patients on biologics but wouldn't typically present with non-caseating granulomas and elevated ACE.\n\nFungal infections might cause granulomas but would typically show organisms on special stains.\n\nAmyloidosis is characterized by amyloid deposits, not granulomas.\n\nThe constellation of non-caseating granulomas and elevated ACE in a patient on a TNF-α inhibitor most strongly points to infliximab-induced sarcoidosis.\n\nThe answer is (B)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-010", "question": "A 42-year-old woman with acromegaly undergoes transsphenoidal surgery, but IGF-1 levels remain elevated postoperatively. She declines further surgery. What is the most appropriate pharmacologic therapy?", "options": ["Cabergoline", "Pegvisomant", "Octreotide", "Pasireotide", "Bromocriptine"], "answer": "B", "answer_index": 1, "explanation": "Pegvisomant, a growth hormone receptor antagonist, is the most effective for normalizing IGF-1 in acromegaly resistant to surgery and somatostatin analogs. Octreotide and pasireotide are somatostatin analogs that may not suffice post-surgery. Dopamine agonists like cabergoline or bromocriptine are less potent for pure GH-secreting adenomas.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "To determine the most appropriate pharmacologic therapy for a patient with persistent acromegaly after transsphenoidal surgery, I need to consider the efficacy of different medication options.\n\nFor acromegaly with persistently elevated IGF-1 levels after surgery:\n\nA. Cabergoline - A dopamine agonist that can be effective in some cases of acromegaly, but has modest efficacy (about 30% normalization rate) and is generally considered second-line therapy.\n\nB. Pegvisomant - A growth hormone receptor antagonist that blocks the peripheral action of GH, directly lowering IGF-1 levels. Very effective for normalizing IGF-1 levels (success rates >90%) when other treatments fail.\n\nC. Octreotide - A first-generation somatostatin receptor ligand (SRL) that is typically considered first-line medical therapy for acromegaly, with moderate efficacy (50-60% biochemical control).\n\nD. Pasireotide - A second-generation SRL with broader somatostatin receptor binding profile than octreotide, potentially more effective but with more side effects.\n\nE. Bromocriptine - An older dopamine agonist with lower efficacy than cabergoline for acromegaly.\n\nFirst-line medical therapy for acromegaly is typically a somatostatin analog like octreotide. If this fails, pegvisomant would be considered. Since this question asks for the most appropriate initial pharmacologic therapy after failed surgery, octreotide would be the standard first choice.\n\nThe answer is (C)"}]